Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
an undetermined dose of GSK1292263 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 6 active 2 placebo |
| Cohort 2 | EXPERIMENTAL | 9 active 3 placebo |
| Cohort 3 | EXPERIMENTAL | Optional cohort |
| Cohort 4 | EXPERIMENTAL | 12 active |
| Cohort 5 | EXPERIMENTAL | 12 active |
| Name | Type | Description |
|---|---|---|
| an undetermined dose of GSK1292263 | DRUG | GSK investigational product or placebo |
| ascending dose of GSK1292263 | DRUG | Ascending dose based on target exposures or placebo |
Inclusion Criteria: * Healthy Male or female between 18 and 55 years of age * A female subject is eligible to participate if she is of non-childbearing potential * Male subjects must agree to use one of the contraception methods listed in the protocol * BMI within the range 20 - 29.9 kg/m2 * Capabl...
GSK1292263 is an investigational small molecule being studied for the treatment of dyslipidaemias, a group of disorders characterized by abnormal levels of lipids in the blood. It is currently in Phase 1 clinical development and has not been approved for any use.
GSK1292263 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for dyslipidaemias.
GSK1292263 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 study in healthy volunteers has been completed to assess its safety, tolerability, and pharmacokinetics.
GSK1292263 has been studied in one completed Phase 1 clinical trial, identified as NCT00783549. This trial enrolled 76 participants in the United States and investigated the safety, tolerability, and pharmacokinetics of single oral doses of the drug in healthy volunteers.
Yes, GSK1292263 has been studied in healthy volunteers. The completed Phase 1 trial NCT00783549 enrolled healthy adult participants aged 18 years and older in the United States. The study was randomized and controlled, and it evaluated the safety, tolerability, and pharmacokinetics of the drug.